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The unprecedented scale of the Ebola outbreak in West Africa has, as of 29 April 2015, resulted in more
than 10,884 deaths among 26,277 cases. Prior to the ongoing outbreak, Ebola virus disease (EVD) caused
relatively small outbreaks (maximum outbreak size 425 in Gulu, Uganda) in isolated populations in central
Africa. Here, we have compiled a comprehensive database of estimates of epidemiological parameters
based on data from past outbreaks, including the incubation period distribution, case fatality rate, basic
reproduction number (R0), effective reproduction number (Rt) and delay distributions. We have compared
these to parameter estimates from the ongoing outbreak in West Africa. The ongoing outbreak, because of
its size, provides a unique opportunity to better understand transmission patterns of EVD. We have not
performed a meta-analysis of the data, but rather summarize the estimates by virus from comprehensive
investigations of EVD and Marburg outbreaks over the past 40 years. These estimates can be used to
parameterize transmission models to improve understanding of initial spread of EVD outbreaks and to
inform surveillance and control guidelines.
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Background & Summary
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is caused by a zoonotic virus ﬁrst
discovered in 1976 in remote villages of Democratic Republic of Congo (DRC, formerly Zaire) and
Sudan1–4. The virus was again identiﬁed in the mid-1990s, when it re-emerged in Gabon and Kikwit,
DRC5,6. Since then, there have been sporadic outbreaks in human and non-human-primate populations,
primarily in remote areas in central Africa (Table 1)7–9. There are ﬁve Ebola viruses: Zaire ebolavirus,
Sudan ebolavirus, Bundibugyo ebolavirus, Tai Forest ebolavirus and Reston ebolavirus. The most lethal is
the Ebola Zaire virus. Ebola Reston is unique among the ﬁve Ebola viruses in that it is not known to cause
disease in humans10 and Ebola Tai Forest has only been reported in 1 human case11. Together with
Marburg virus, Ebola forms the Filoviridae family (ﬁlovirus)8.
The primary reservoir of the Ebola virus is believed to be fruit bats12,13. However, non-human
primates, including chimpanzees, gorillas, and cynomolgus monkeys, and forest antelopes have been
reported as possible vectors in transmission to humans14, and EVD has caused devastating mortality in
non-human-primate populations15. Once infected, the symptoms of human EVD are non-speciﬁc and
typically include fever, headache, joint or muscle pain, sore throat, vomiting, and/or diarrhea15–17. More
severe cases involve hemorrhagic manifestations, shock and other neurological symptoms14,16–21.
While it has been difﬁcult to trace the source of human outbreaks, it is believed that EVD outbreaks
usually start from a zoonotic source with subsequent human-to-human transmission22,23. Transmission
between humans occurs through exposure to infectious bodily ﬂuids, typically from close contact with
infectious individuals when caring for EVD patients (e.g., sharing of contaminated needles, family home
Outbreak Year Ebola virus Number of conﬁrmed, probable and suspected cases
Yambuku, DRC2 1976 Zaire 318
South Sudan1 1976 Sudan 284
Nzara, Sudan24 1979 Sudan 34
Gabon6 1994–1995 Zaire 49
Kikwit, DRC5 1995 Zaire 315
Maybout, Gabon* 1996 Zaire 37
Booue, Gabon6 1996–1997 Zaire 60
South Africa74 1996 Zaire 2
Gulu, Uganda45,52,53 2000–2001 Sudan 425
Republic of Congo and Gabon75 2001–2002 Zaire 65 in Gabon, 59 in Congo
Republic of Congo25,72 2002–2003 Zaire 143
Mbomo, Republic of Congo25 2003 Zaire 35
Yambio, South Sudan† 2004 Sudan 17
Etoumbi, Republic of Congo25 2005 Zaire 12
Kasai Occidental Province, DRC23 2007 Zaire 264
Bundibugyo District, Uganda47 2007–2008 Bundibugyo 116
Kasai Occidental Province, DRC‡ 2008–2009 Zaire 32
Orientale Province, DRC§ 2012 Bundibugyo 77
Kibaale District, Uganda|| 2012 Sudan 24
Luwero District, Uganda¶ 2012–2013 Sudan 7
Équateur province, DRC49 2014 Zaire 69
West Africa# 2014–2015 Zaire >26,000
Table 1. Human Outbreaks of Ebola Zaire, Ebola Sudan and Ebola Bundibugyo from 1976 to present.
Outbreaks with more than 1 case are included in the table. DRC=Democratic Republic of Congo; The
outbreak in West Africa includes cases from the following countries: Guinea, Liberia, Mali, Nigeria, Senegal and
Sierra Leone, Spain, United Kingdom, and United States. *Reference: WHO 26 April 1996 Disease Outbreak
News. 1996- Ebola haemorrhagic fever in Gabon- Update3: www.who.int/csr/don/1996_04_26b/en/.
†Reference: WHO 7 August 2004: WHO announces end of Ebola Outbreak in Southern Sudan:
www.who.int/csr/don/2004_08_07/en/. ‡Reference: WHO Disease Outbreak News:
www.who.int/csr/don/2009_02_17/en/. §Reference: www.cdc.gov/vhf/ebola/outbreaks/history/summaries.html.
||Reference: WHO Disease Outbreak News: www.who.int/csr/don/2012_09_03/en/. ¶Reference: WHO Disease
Outbreak News: www.who.int/csr/don/2012_11_30_ebola/en/. #Outbreak is ongoing in Guinea, Liberia and
Sierra Leone. Case count reﬂects cases reported as of 29 April 2015.
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care, insufﬁcient protective measures among health care workers in health care settings6,24,25) or with
fatal EVD patients in preparation for burial19,20. Control measures for EVD are well documented and
include identiﬁcation, isolation and care of suspected patients, strict infection prevention and control
among those caring for patients and safe burials26,27.
At the start of an infectious disease outbreak, it is critical to understand the transmission dynamics of
the pathogen and to determine those at highest risk for infection or severe outcomes in the population(s)
affected28,29. This information is needed to develop interventions to reduce the spread of disease and to
reduce morbidity and mortality in the affected populations. Real-time analysis of any ongoing outbreak
by analyzing detailed information collected on the conﬁrmed, probable and suspected cases and deaths
provides an opportunity to determine the stages of disease and areas where control measures can be
applied. For example, knowledge of the incubation period distribution of the pathogen will inform the
duration of time required to follow up the contacts of cases to evaluate whether or not they become
secondary cases. Additionally, information on the timing of symptom onset, isolation, hospitalization and
outcome (either death or recovery) are important to understand EVD progression. Mathematical models
which make use of available data early in an outbreak to estimate the outbreak’s potential impact
are increasingly used by public health policy makers to inform decision making around emerging and
re-emerging pathogens28–30.
The purpose of this review was to collect all published epidemiological parameter estimates (reprinted
in detailed tables containing estimates, and corresponding conﬁdence intervals) estimated from past EVD
outbreaks. Our aim was not to perform a meta-analysis, but rather to compile and document the available
parameter estimates based on data from EVD outbreaks over the past 40 years. In order to estimate any
of the parameters referenced in our manuscript, we would need detailed case data of each of the cohorts
studied in the original papers, which we do not have. We also reprint parameter estimates from past
Marburg outbreaks and the ongoing outbreak in West Africa for comparison. This information is
valuable for public health organizations that need to quickly evaluate the early behavior of a new outbreak
and estimate the potential impact, in terms of morbidity, mortality and geographic spread. We highlight
how the parameter estimates we have examined improve our understanding of EVD epidemiology. Our
results help to put the ongoing EVD outbreak in West Africa into context and to assess the likely effects
of ongoing and novel interventions.
Methods
Data collection
All searches using the following search terms (Ebola, Marburg, EHF, EVD, MHF, EBOV, Ebola Zaire,
Ebola Sudan, Ebola Reston, Ebola Bundibugyo, outbreak, model, parameterization, incubation period, case
fatality rate, case fatality rate (CFR), risk factors, basic reproduction number, R0, effective reproduction
number, serial interval, delay distributions, generation time) were carried out on 1 August 2014, 15
September 2014 and again in February 2015 using the following databases: ScienceDirect, ResearchGate,
Google, GoogleScholar, BioOne, Web of Science and PubMed. Our searches aimed to ﬁnd primary
reports describing and analyzing data collected from investigations of EVD and Marburg outbreaks since
the virus was identiﬁed in 1976. The criteria for inclusion were: sample size of EVD cases described in the
study ≥5, studies of human outbreaks, studies which evaluated potential risk factors had to report
prevalence proportion ratios, odds ratios or relative risks. Reviews, commentaries, case reports on
individual cases, and policy pieces were excluded. Additionally, literature evaluating non-human
outbreaks or the potential for international (human) spread of EVD outside of an outbreak zone was
excluded.
Using these search terms, a total of 49 papers were determined eligible for inclusion. In addition, for
context we included additional published information on EVD including the ﬁnal outbreak sizes as
reported by the World Health Organization (WHO) Disease Outbreak News following declaration that
each outbreak was over.
From the relevant EVD and Marburg literature, we extracted the following details for all parameter
estimates (as provided): point estimates, conﬁdence intervals, ranges, sample size used to estimate the
parameter (total numbers of cases encompassing conﬁrmed, suspected, and retrospectively diagnosed
cases, depending on the study), EVD virus, and inferential methods. We then compiled the parameter
estimate database into tables. Table 1 and Data Citation 1 list the human outbreaks of Ebola Zaire, Ebola
Sudan and Ebola Bundibugyo that have occurred in Africa from 1976 to present. We have not provided
detailed information on the outbreaks as these have been previously described9. Table 2 (available online
only) summarizes the literature we used in this review.
Our manuscript and tables include estimates, conﬁdence intervals and ranges obtained from the
referenced publications (Table 2 (available online only) and Data Citation 2).
Deﬁnition of key parameters recorded
The incubation period is the interval between exposure to a pathogen and initial occurrence of symptoms
and signs28,29. The incubation period distribution is usually characterized using the mean or the median
incubation period.
The CFR is the proportion of cases (infected symptomatic individuals) within a designated population
who die as a result of their infection. For past EVD and Marburg outbreaks, we report on the CFR
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estimated after the outbreak was declared over (estimated at least 42 days after the last case experienced
symptom onset) by taking the number of deaths among cases divided by the total number of cases
recorded during the outbreak. However, during outbreaks, the CFR is often estimated before all cases
have been identiﬁed and before some cases have either recovered or died.
Risk factors for infection include demographic factors, medical conditions and behavioral exposures or
practices that are associated with an individual’s risk of becoming infected with Ebola.
The basic reproduction number (R0) is used to measure the transmission potential of a disease. It is
the average number of secondary infections produced by an infected case in a susceptible population31.
If R0 >1, then once established the outbreak will continue, whereas if R0o1, then the outbreak will
die out.
The effective reproduction number (Rt) is similar to R0 but relates to a particular calendar time t (after
the start of the outbreak). Like R0, if Rt>1, then the outbreak will continue, whereas if Rto1, then the
outbreak will die out. Rt can be reduced through the use of successful control measures (e.g., by limiting
contacts between susceptible and infectious individuals). Rt can also be reduced due to the depletion of
susceptible individuals whether through extensive transmission or through the immunization of
susceptible individuals32.
The serial interval is the interval between symptom onset in an index case and symptom onset in a
secondary case infected by that index case33.
The generation time is the interval between infection of an index case and infection of a secondary
case infected by that index case. The serial interval is more frequently estimated than the generation time
and is often assumed to be the same duration as the generation time34.
Delay distributions
Symptom onset to hospitalization (also referred to as onset to clinical assessment): The interval between
symptom onset and hospitalization.
Hospital admission to day of ﬁrst blood sample: The interval between admission to hospital or medical
facility for treatment of EVD and when a biological sample is collected for diagnosis.
Symptom onset to recovery/discharge: The interval between symptom onset and recovery or hospital
discharge.
Symptom onset to death: The interval between symptom onset and death.
Duration of admission (survivors)—hospitalization to discharge: The interval between admission to a
hospital or medical facility for treatment of EVD and discharge from the facility.
Duration of admission (fatal cases)—hospitalization to death: The interval between admission to a
hospital or medical facility for treatment of EVD and death.
Data Records
The data from this analysis are summarized in two types of data format. Four data tables detail the
methods and parameter estimates from each study included in our review. Our data tables:
Table S1: Human Outbreaks of Ebola Zaire, Ebola Sudan and Ebola Bundibugyo from 1976 presents
compiled data on the year and location of the each human outbreak, the Ebola Virus causing the outbreak
and number of cases reported (Data Citation 1).
Table S2: Parameter Estimates by Outbreak presents a comprehensive list of parameter estimates,
including incubation period distribution, reproduction number, serial interval distribution, generation
time distribution, delay distributions, and CFR by Ebola virus and study (Data Citation 2).
Table S3: Parameter estimates for the ongoing EVD outbreak in West Africa presents published estimates
of delay distributions and CFR for the ongoing outbreak in West Africa (Data Citation 3).
Table S4: Risk factors for EVD and Marburg infection presents published results from outbreak (Data
Citation 4).
Using these four tables, we then summarized the parameter database in six tables and two ﬁgures
presented in this article. The parameters estimated for Ebola Zaire, Ebola Sudan and Ebola Bundibugyo
outbreaks, including the incubation period distribution, serial interval distribution, R0, delay distributions
and CFR, are shown in Tables 3 (available online only), 4 (available online only), 5, respectively.
Parameter estimates for the ongoing outbreak in West Africa are summarized in Table 6 (available online
only) and for Marburg outbreaks are presented in a single table (Table 7). Risk factors for Ebola and
Marburg infection are summarized in Table 8 (available online only). Estimates of the incubation period
distribution and CFR are presented in Figs 1 and 2, respectively.
Technical Validation
Incubation period distribution
The incubation period distribution of EVD has been estimated for past EVD outbreaks (Fig. 1 and
Tables 3 (available online only), 4 (available online only), 5; minimum sample size n= 5, maximum
sample size n= 1,798). The mean (or median) incubation period (Fig. 1), for the different Ebola viruses
www.nature.com/sdata/
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ranged from 3.35 to 12.7 days (range 1–21 days), excluding an extreme outlier35. Central estimates for the
incubation period distribution were between 5.3–12.7 days (range 1–21 days) for Ebola Zaire5,6,16,17,36–43,
3.35–12 days (range 1–16 days) for Ebola Sudan1,44,45, and 6.3–7 days (range 2–20 days) for Ebola
Bundibugyo46,47.
The mean incubation period for the ongoing Ebola outbreak in West Africa has been estimated to be
between 9–12 days (Table 6 (available online only))16,17,41,48. The range of incubation periods observed in
past EVD outbreaks supports the policy of contact tracing for 21 days following contact with an EVD
patient. An outbreak is ofﬁcially declared over after no new cases are identiﬁed 42 days (2 times the
21-day maximum incubation period) after the last EVD case is found.
Case fatality rate (CFR)
In Fig. 2 and Tables 3 (available online only), 4 (available online only), 5, we reprint the estimated CFR
for each Ebola outbreak (by virus) and for Marburg virus. The Ebola Zaire virus is the most lethal with an
overall estimated CFR ranging from 69 to 88%2,5,25,38,43,49,50 (Table 3 (available online only)). The CFR of
outbreaks due to Ebola Sudan virus ranged from 53 to 69%1,24,51–53 (Table 4 (available online only)), and
the CFR of outbreaks due to Ebola Bundibugyo ranged from 34 to 42%19,46,47 (Table 5). For the ongoing
outbreak in West Africa due to Ebola Zaire, the estimated CFR, as measured among conﬁrmed and
probable cases with deﬁnitive outcome (recovered or fatal), is approximately 70%, and varies little among
Parameter Estimate Estimate
Incubation Period Distribution (days) (mean, (95% CI), median, (range)) * 6.3 (5.2, 7.3), Med= 7 (2–20)
Delay Distributions (days)
Symptom onset to…
… hospitalization 3.5
Roddy et al. (median, (range), n)19 Med= 3.5 (0–8), n= 26
… death (range of medians) 9–10
Roddy et al. (median, (range), n)19 Med= 9 (3–20), n= 11
Wamala et al. (median, (range), n)47 Med= 10 (3–21), n= (NP)
…recovery 10
Wamala et al. (median, (range), n)47 Med= 10 (2–26), n= (NP)
Case Fatality Rate † (range of estimates) 0.34–0.42
MacNeil et al. (estimate, n, year of outbreak)46 0.40, n= 43‡, 2007
Wamala et al. (estimate, n, year of outbreak)47 0.34, n= 116, 2007
Roddy et al. (estimate, n, year of outbreak)19 0.42, n= 26 (hospitalized conﬁrmed), 2007–08
Table 5. Parameter Estimates for Ebola Bundibugyo. Med=median; (NP)=Not Provided. *See Fig. 1 for
individual estimates. †See Fig. 2 for CFR estimates. ‡Conﬁrmed cases only.
Parameter Estimate
Generation Time Distribution (days) (mean, 95% CI, s.d., n)* 55 9 (8.2, 10), 5.4, n= 374
R0 (estimate, 95% CI) 1.59 (1.53, 1.66)
Delay Distributions (days)
Symptom onset to death (range of medians) 7–8
Ajelli & Merler (median, range, n)55 Med= 7 (5–9), n= 329
Colebunders et al. (median, range, n)57 Med= 8 (2–16), n= 40
Case Fatality Rate † (range of estimates) 0.78–0.88
Ajelli & Merler (estimate, 95% CI, n, year of outbreak)55 0.88 (0.84–0.91), n= 374, 2005
Bausch et al. (estimate, n, year of outbreak)56 0.83, n= (NP), 1998
Colebunders et al. (estimate, n, year of outbreak)57 0.78, n= 77, 1998
Table 7. Parameter Estimates for Marburg. Med=median; s.d.= standard deviation; (NP)=Not Provided.
*Authors refer to generation time, but have estimated the serial interval and assumed serial interval is the same
as generation time. †See Fig. 2 for CFR estimates.
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Figure 1. Estimates of the incubation period distribution by virus, year of outbreak and study. The dots
represent the mean or median estimate and the lines illustrate the range, for all studies, with the exception of
MacNeil et al.46 and WHO Ebola Response Team (ERT) 201517 (ﬁtted) where the line represents the 95% CI
for the estimate. Chowell et al.44, Eichner et al.40, WHO ERT 2014 (multi-day observed)16 and Lekone and
Finkenstädt42 provide standard deviation (s.d.).
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Figure 2. Overall case fatality rate (CFR) for Ebola by virus and Marburg virus; we include only those outbreaks
that have been declared over. Outbreaks with fewer than 10 fatal patients were excluded from this ﬁgure. For each
outbreak, the bars represent the rate of fatal (dark color) and recovered (light color) patients. For country speciﬁc
information see Table 1. The source of each estimate is denoted by the reference number at the top of each bar.
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the three most affected countries (Guinea, Liberia and Sierra Leone; Table 6 (available online only) and
Data Citation 2)38. The CFR among EVD cases reported by Nigeria (n= 20) was 40%54. A second,
unrelated EVD outbreak occurred in Équateur province, DRC between July and October 2014 resulting in
69 conﬁrmed and probable cases with a CFR of 74%49. The CFR for Marburg is approximately 80%55–57.
R0 and Rt
Looking at past outbreaks, estimates of R0 for Ebola Zaire ranged from 1.4-4.7
35,42,44,58–60 (Table 3
(available online only) and Data Citation 2), and for Ebola Sudan ranged from 1.3-2.744,58–60 (Table 4
(available online only)). R0 has not been estimated for Ebola Bundibugyo.
In the ongoing outbreak in West Africa, estimates of R0 and Rt have been estimated for all countries
combined, as well as separately for Guinea, Liberia, Nigeria and Sierra Leone16,30,36,41,48,54,61–69. All
estimates of Rt are provided in Table 6 (available online only) and Data Citation 2 and Data Citation 3.
Gomes et al.62 reported several all-country R0 estimates (means ranging 1.8–2.1), depending on model
choice and assumptions. Fisman et al.30 reported all-country and country-speciﬁc R0 estimates depending
on assumptions including action taken to mitigate infection. For the most part, R0 estimates for Guinea,
Liberia, and Sierra Leone ranged from 1.2 to 2.5 with the striking exception of the Fisman et al.30 R0
estimate of 8.3 for Sierra Leone. Nishiura and Chowell65 estimated Rt ﬂuctuating around 1 for Guinea, 1.7
for Liberia and 1.4 for Sierra Leone. The WHO Ebola Response Team16 estimated Rt for Guinea (ranging
from 1.6 to 2.0), for Liberia (ranging from 1.4 to 1.6) and for Sierra Leone (ranging from 1.3 to 1.5).
Several groups have also estimated R0 for speciﬁc geographic areas within the region (full details in
Table 6 (available online only) and Data Citation 2). For example, Faye et al. estimated R0 for cases
occurring in Conakry, Guinea at the start of the outbreak (n= 193)41 as 1.7 (95% CI 1.2, 2.3); whereas
Lewnard et al.64 estimated R0 for EVD cases in Montserrado, Liberia as of October 2014 (R0= 2.5
(2.4, 2.6)).
Serial interval distribution
The serial interval, deﬁned as the time interval between symptom onset in an index case and symptom
onset in a secondary case infected by that index case, has been infrequently estimated due to the paucity
of data on epidemiologically linked pairs of index and secondary cases. For Ebola Zaire (Table 3 (available
online only)), the mean serial interval was estimated to be 10–16.1 days5,49,60,70. In the ongoing outbreak
in West Africa, the mean serial interval has been estimated to be approximately 14–15 days16,17,30,41
(Table 6 (available online only)).
Generation time distribution
Closely related to the serial interval, the generation time is deﬁned as the time interval between infection
of an index case and infection of a secondary case infected by that index case. As such, the generation
time distribution nearly always needs to be inferred indirectly from serial interval observations and
knowledge of the incubation period distribution. We found one such estimate of the mean generation
time for Marburg of 9 days (95% CI 8.2, 10.0)55.
Delay distributions
For Ebola Zaire, including the ongoing outbreak, the mean time from symptom onset to hospitalization
(Table 3 (available online only) and Table 6 (available online only)), ranged from 3.2 to 5.3
days5,16,17,20,38,41,48, whereas the mean time from symptom onset to death ranged from 6 to 10.1
days5,17,25,37–39,41,49,61. For Ebola Sudan (Table 4 (available online only)), the mean time from symptom
onset to hospitalization was 2 days (range 0–8)51 and the median time from symptom onset to death was
9 days (range 5–15)24, respectively. The mean time from hospitalization to discharge for Ebola Sudan
ranged from 8 to 10 days51,53 whereas the mean time from hospitalization to death was 6.1 days (range
2–13)51. For Ebola Bundibugyo (Table 5), the median time from symptom onset to hospitalization was
3.5 days (range 0–8)19 and the median time from symptom onset to death was 9–10 days (range 3–21
days)19,47.
Risk for developing EVD
Risk factors for human-to-human transmission of EVD or Marburg were evaluated from comparison of
the exposures, behaviors and practices in cases compared to controls (including unaffected controls,
deﬁned to be suspected cases but negative serologic test results) and were described using a prevalence
proportion ratio, an odds ratio or a relative risk (and the corresponding conﬁdence interval). Signiﬁcant
risk factors associated with developing EVD are reported in Table 8 (available online only) and Data
Citation 4 and include direct physical contact (sharing a bed, touching a cadaver or funeral preparations
for an EVD patient, nursing care and contact with bodily ﬂuids) and non-physical contact (sharing a
meal, contact with a hospital where EVD patients were treated)24,39,45,47,56,71.
Usage Notes
The data presented in this review summarize estimates of the epidemiological parameters of EVD and
Marburg. These results can facilitate parameterization and sensitivity analysis of transmission models
examining surveillance, control and treatment strategies. The results can also inform epidemiological
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studies investigating human-to-human transmission during Ebola and Marburg outbreaks, deepening
our understanding of the transmission process.
The number of parameters estimated for each outbreak has generally increased with time (Table 2
(available online only)). While the incubation period distribution was consistently assessed, R0 has
increasingly been estimated, most notably with the ongoing outbreak in West Africa (Table 6 (available
online only) and Data Citation 2). Fig. 1 shows the central estimates and ranges for the different studies
that estimated the incubation period distribution for EVD outbreaks. While there are small differences in
the central estimates of the incubation period distribution of the four Ebola viruses, the ranges around the
mean or median are consistent, with a maximum of ≤21 days. Current EVD guidance states that EVD
has an incubation period of 2–21 days, which is the basis for the recommended duration of contact
tracing of 21 days26,27. This is supported by the ﬁndings in our review.
Figure 2 shows CFR for different Ebola Zaire, Ebola Sudan, Ebola Bundibugyo and Marburg outbreaks.
While the CFR for Ebola and Marburg are high (compared to other infectious diseases), outbreaks caused
by Ebola Zaire and Ebola Sudan have experienced the highest CFR amongst these three Ebola viruses
causing outbreaks in humans1,2,5,19,24,25,38,43,46,47,50–53,72–76. The estimated CFR for the ongoing outbreak
in West Africa, due to Ebola Zaire, is approximately 70%16,17,36, which falls within the range of CFRs for
past outbreaks due to this virus2,5,25,38,43,50.
Figure 2 also illustrates that recent CFR estimates for Ebola Zaire remain comparable to those
observed in the 1970s. While there are ongoing efforts to develop medical treatments for EVD, treatment
remains mainly supportive. The massive scale of the ongoing outbreak has highlighted the urgent need to
develop new treatments and to fast track the use of experimental medical interventions77.
The transmission potential, as measured by R0, is fairly consistent among the three Ebola viruses,
ranging from approximately >1 to 4 (also mentioned in ref. 78). Previously, EVD typically affected
villages in remote areas of central Africa35,38,42,44,58,59, and while devastating in these areas, the
populations that are at risk are generally limited in number. The ongoing EVD outbreak had circulated
for at least three months prior to discovery22,79 which allowed spread of the virus to go unchecked while it
infected people in an area of Guinea that shares borders with Sierra Leone and Liberia. Recent experience
in Nigeria, has shown that an Ebola virus with R0>1, even in a population of over 20 million, can be
controlled with vigorous application of control methods49,54.
Differences in estimates of R0 and Rt are likely, at least in part, to be the result of the quality of data
available and the inferential method. The focus on R0 estimation together with serial interval estimates
may reﬂect a shift from data collection purely for surveillance to recognition of the epidemiological value
of such data.
The speciﬁc factors that result in an EVD outbreak have been under investigation since the emergence
of this virus and include examination of human and susceptible non-human populations living in close
proximity with each other in remote areas of central Africa. Recent investigations into the ﬁrst cases of
the ongoing outbreak found that the outbreak may have begun in Meliandou, Guinea in a village where
the inhabitants frequently came in contact with fruit bats in a hollowed out tree80. Although the current
focus is on limiting human-to-human transmission and treating the infected, the challenging underlying
factors that led to this large outbreak in West Africa will require long-term investments to improve both
health care and surveillance for infectious diseases.
Our dataset is the most complete collection of published epidemiological parameter estimates from
EVD outbreaks available at the time of writing and provides an evidence-based foundation for both
retrospective analyses and responses to future outbreaks.
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